MediWound : Presentation - January 2021

Company Presentation

January 2021 I Nasdaq: MDWD

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. We make forward-looking statements in this presentation that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The statements we make regarding the following matters, among others, are forward-looking by their nature: the timing and conduct of our trials of NexoBrid and our other pipeline product candidates, including statements regarding the timing, progress and results of current and future preclinical studies and clinical trials, and our research and development programs; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of NexoBrid and our pipeline products; our expectations regarding future growth, including our ability to develop new products; our commercialization, marketing and manufacturing capabilities and strategy and the ability of our marketing team to cover regional burn centers and units; our ability to maintain adequate protection of our intellectual property; our plans to develop and commercialize our pipeline products; our estimates regarding the market opportunity for NexoBrid and EscharEx; the design of the Phase 2 study of EscharEx, the timeline for the Phase 2 study and the interim report; our development plan for second generation EscharEx; the ability to fit EscharEx into treatment workflow and reimbursement programs; our expectations regarding the wound care market; the potential utility of EscharEx; and our ability to successfully develop and commercialize EscharEx. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several important factors. In particular, you should consider: the FDA may not consider the Phase 2 study to be an adequate controlled study for the purpose of filing a BLA; the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our trials of NexoBrid, EscharEx and our other pipeline product candidates, including the timing, progress and results of current and future preclinical studies and clinical trials, and our research and development programs; risks related to our collaboration with Vericel; our ability to obtain marketing approval of NexoBrid and EscharEx in the U.S. or other markets; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of NexoBrid, EscharEx and our pipeline products; our expectations regarding future growth, including our ability to develop new products; our commercialization, marketing and manufacturing capabilities and strategy and the ability of our marketing team to cover regional burn centers and units; risks related to our contract with the U.S. Biomedical Advanced Research and Development Authority; market acceptance of our products and product candidates; the possibility of unfavorable pricing regulations or lack of coverage by third parties and reimbursement policies; our operating expenses and history of net losses; our dependence on third party suppliers; our dependence on our manufacturing facility in Yavne, Israel and related manufacturing risks; our ability to maintain adequate protection of our intellectual property; side effects of our products and product candidates; competition risks; exchange rate fluctuations; litigation risks; risks related to our operations in Israel; our estimates regarding expenses, future revenues, capital requirements and the need for additional financing; the impact of government laws and regulations; and the additional risks discussed under the heading "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2019 as well as information contained in other documents filed with or furnished to the Securities and Exchange Commission. Any forward-looking statement made in this presentation speaks only as of the date hereof. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation, to conform these statements to actual results or to changes in our expectations.

Trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company. Certain data in this presentation, including the market research data contained on slides 8-11 and 16, was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or to update such data after the date of this presentation. Such data involves risks and uncertainties and is subject to change based on various factors.

The U.S. phase 3 study, pediatric phase 3 study, expanded access treatment protocol and the registration process for NexoBrid in the U.S. as well as the development of NexoBrid for Mustard Sulfur injuries, are funded in whole or in part with Federal funds provided by the Biomedical Advanced Research and Development Authority (BARDA), under the Assistant Secretary for Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), under ongoing USG Contracts No. HHSO100201500035C and No. HHSO100201800023C. We maintain our books and records in U.S. Dollar and report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board. None of the consolidated financial statements incorporated by reference into this prospectus supplement were prepared in accordance with generally accepted accounting principles in the United States. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of MediWound or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of MediWound.

About Us

Creating innovative

therapeutic solutions for

better quality of care

Innovative biopharmaceutical company

Focused on the development and commercialization of novel, cost-effectivebio-therapeutics

One commercial product and one late-stage clinical product

Proprietary proteolytic enzyme platform technology

Clinical and commercial validation

Development and manufacturing expertise

Well capitalized

State-of-the-art, cGMP certified sterile manufacturing facility

Strong management with proven execution capabilities

3

Executing Our Strategy

NexoBrid®

Next Gen Burn Debridement

• Biological orphan drug
• Indication: eschar removal of deep partial and full thickness burns
• EU and international market approvals in hand
• BLA was filed in June 2020
• U.S. Expanded Access program underway
• Substantial U.S. government support (BARDA)
• Commercial collaboration with Vericel for North America
• TAM* (U.S.): >$200 million

EscharEx®

Enzymatic Debridement Agent

• Biological drug candidate
• Indication: debridement of chronic/hard- to-heal wounds (VLU's/DFU's/pressure ulcers)
• De-riskeddevelopment plan
• U.S. Phase 2 adaptive design study underway
• Significant market opportunity for enzymatic debridement
• Market access strategy under existing reimbursement codes
• TAM* (U.S.): >$2 billion

MWPC003

Injectable Enzyme Therapy

• Biological drug candidate
• Indication: treatment of connective tissue disorders such as:
• • Scars
  • Dupuytren's Contracture
  • Peyronie's Disease
• Pre-clinicalstudies already completed
• TAM* (U.S.): >$1 billion

*TAM - Targeted addressable market

4